BioVaxys Technology Corp. (OTC: BVAXF) is a clinical-stage biopharma company developing antiviral and anticancer vaccines. Currently, BVAXF is focused on developing and evaluating a potential SARS-CoV-2 vaccine by utilizing its haptenized viral protein technology. After filing an international patent application for a SARS1 vaccine, BVAXF stock soared by as much...
Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...
BIOV.C may have found a bottom at ~ .19 after filling the gap with insiders recently buying at over .30. Approaching oversold area on the Daily chart.
BIOV is breaking out after a series of very promising press releases concerning their COVID-19 and cancer treatment/vaccine solutions. Still under the radar and will likely see lots of upside from here.